These results showed that the HLA-G/KIR2DL4 interaction can promote breast cancer resistance to trastuzumab in vivo by circumventing NK cell killing and that KIR2DL4 on tumor-infiltrating NK cells can play different roles depending on the availability of HLA-G. Here, KIR2DL4 is linked to breast carcinoma.